OHSU

IRB #

IRB00009554

Title

A single-arm, multicenter, nilotinib treatment-free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease (MRD) status on first line nilotinib treatment.

Principal Investigator

Brian Druker

Study Purpose

The purpose of this study is to learn if the study drug, nilotinib, can be safely stopped being taken with no return of CML in patients who responded well on the treatment in the past.

Medical Condition(s)

chronic myeloid leukemia (CML)

Eligibility Criteria

Patients with chronic myeloid leukemia (CML) who started treatment with nilotinib when they were first diagnosed with CML and continued this treatment for at least 24 months and have only a very small amount of leukemia cells remaining are eligible for the study.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

244 weeks (about 5 years)

Minors Included

No

Contact

Nan Subbiah
503-494-4603
subbiahn@ohsu.edu

or

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Novartis Pharmaceuticals, Inc.

Recruitment End

04/11/2025

Compensation Provided

No


Go Back